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Abstract
We utilised the IMPATTO study’s archives to describe the 2000-2008 colorectal cancer (CRC) incidence
rate trends in Italy, once screening programmes based on the faecal immunochemical test were im-
plemented in different areas.
Data on CRCs diagnosed in Italy from 2000 to 2008 in subjects aged 40-79 years were collected by
23 cancer registries. Incidence rate trends were evaluated as a whole and by macro-area (North-Cen-
tre and South-Islands), presence of a screening programme, sex, ten-year age class, anatomic site, stage
at diagnosis, and pattern of diagnosis (screen-detected, non-screen-detected). The annual percent
change (APC) of incidence rate trends, with 95% confidence intervals (95%CI), were computed.
The study included 46,857 CRCs diagnosed in subjects aged 40-79 years, of which 2,806 were screen-
detected. The incidence rates in the North-Centre were higher than in the South and on the Islands.
During the study period, screening programmes had been implemented only in the North-Centre and
had a significant effect on incidence rates, with an initial sharp increase in incidence, followed by a
decrease that started in the 3rd-4th years of screening. These incidence rate trends were exclusively
due to modifications in the rates of stage I cases. After screening programmes started, incidence in-
creased in all anatomic sites, particularly in the distal colon.
The differential figures introduced by the implementation of screening programmes warrant a con-
tinuous surveillance of CRC incidence and mortality trends to monitor the impact of screening at a na-
tional level.
(Epidemiol Prev 2015; 39(3) Suppl 1: 115-125)
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Riassunto
E’ stato utilizzato l’archivio dello studio IMPATTO per descrivere i trend di incidenza del tumore
del colon retto (CCR) in Italia nel periodo 2000-2008, quando sono stati avviati programmi di scree-
ning colorettale basati sul test per la ricerca del sangue occulto fecale in diverse aree.
23 Registri tumori hanno fornito i dati relativi ai CCR diagnosticati nel periodo 2000-2008 in sog-
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INTRODUCTION
Colorectal cancer (CRC) is a major public health problem. In
Italy it represents themost frequent tumour in terms of incidence
with more than 50,000 new cases and is the second cause of
death among cancers, with about 19,000 deaths per year.1
According to estimates by the Italian Association of Cancer
Registries (AIRTUM), mortality rates showed a reduction in
both genders starting in the early 1990s, while incidence rates
increased, particularly in males.2
A number of case series from cancer registries in the North of
Italy showed that at the end of the 1990s the proportion of cases
that wereTNM stage III or IV at diagnosis still ranged between
39% and 51% of the total.3-5 Stage at diagnosis is well known
to be closely related to prognosis: a case series from the SEER
study showed a 5-year survival of 93% for cases at AJCC stage
I, 80% for those at stage II, 58% at stage III, and only 7% at
stage IV.6 The SEER study compared series of cases diagnosed
in different periods (from 1973 to 1997) and showed that the
increase in stage-specific survival had been very limited.7
Therefore, the reported increase in survival, from 51% in 1990-
1992 to 64% in 2005-2007,8 is plausibly associated with a
more favourable distribution of stage at diagnosis, which derived
from the spread of the uptake of exams for early diagnosis, first
spontaneously and then within organized screening programmes
(SP). The distribution by stage at diagnosis of screen-detected
CRCs is better than that of clinically diagnosed CRCs, with
more than 50% of cases at stage I, while those at stage III or IV
are about one-fourth of the total.9-11
In Italy, CRC SPs were progressively implemented in most re-
gions starting in the early 2000s. By the end of 2010, 66% of
the Italian population lived in areas with active CRC screening
programmes, but strong geographical differences were present:
the corresponding figures were 87% in the North, 79% in the
Centre and only 29% in the South and Islands.9
Four randomized controlled trials showed that SPs based on the
guaiac faecal occult blood test (gFOBT) reduce mortality by
16%,12,15-19 which rises to 23% in the per-protocol analysis.12
Results from a gFOBT population-based SP showed similar fig-
ures,13 while early evidence from faecal immunochemical test
(FIT)-based programmes reported a greater reduction in mor-
tality that began earlier compared to the trials, i.e., in the 5th year
after screening started.14
A population-based SP is expected to initially increase incidence
rates, thanks to the diagnostic anticipation of cancers that would
otherwise be diagnosed later. In the medium and long term, a
progressive reduction of incidence rates is expected, deriving from
the prevention of new CRCs as a result of the detection and re-
moval of a large number of precancerous lesions (i.e., advanced
adenomas). As a matter of fact, the four trials showed contrast-
ing effects on the incidence rates, with a 17-20% reduction in one
of them15-16 but no effect in the other three.17-19 The latter re-
ported low compliance with the study by the enrolled subjects
(respectively 67%, 60%, and 63%).
A recent paper showed a reduction of incidence rates in the
medium term (22% 11 years after screening started).20 Many
studies have shown that FIT sensitivity for advanced adenoma
and cancer is higher than that of gFOBT.21-26 Thus the effect
on incidence observed in screening programmes and not in tri-
als could be due to FIT having a higher sensitivity for adenomas
than gFOBT.
In Italy, CRC SPs are aimed at residents aged 50-69 or 74 years,
who are invited via mail every 2 years to perform a single FIT.
Subjects with a positive screening test are contacted to undergo
a total colonoscopy performed at an endoscopic referral centre.
In only one region (Piemonte) has a different programme been
established, with either one sigmoidoscopy at the age of 58, or a
FIT invitation every 2 years in the age interval of 59-69 years.The
average detection rate of advanced adenomas in organized pro-
grammes in Italy is high, compared to that of guaiac trials,18,27
reaching 13 x 1,000 at the prevalence round and 8 x 1,000 at the
incidence round, respectively.11 Consequently, the impact of
screening programmes on incidence is an open question.
To describe the impact that implementing CRC screening pro-
grammes has had in Italy, a research project, the IMPATTO
study, was financed by the ItalianMinistry of Health; the study
collects and links information from both screening programme
archives and cancer registries.
This paper utilizes the IMPATTO study’s archives to describe the
CRC incidence rate trends in Italy during 2000-2008, when sev-
eral SPs were implemented in different areas.
getti di età compresa fra 40 e 79 anni. Sono stati calcolati i trend di incidenza complessivi e per macroarea (Centro-Nord e Sud-
Isole), presenza di un programma di screening, sesso, età, localizzazione anatomica, stadio alla diagnosi e modalità diagnostica
(screen-detected, non-screen-detected). Sono riportati gli APC (annual percent change) con intervalli di confidenza al 95%.
L’archivio riguarda 46,857 CRC, di cui 2,806 screen-detected. I tassi di incidenza nel Centro-Nord erano maggiori rispetto
al Sud-Isole. Nel periodo di studio sono stati avviati programmi di screening solo in aree del Centro-Nord, con un effetto
significativo sui tassi di incidenza, con un ripido incremento iniziale seguito da una riduzione a partire dal 3°-4° anno dal-
l’avvio dei programmi. L’effetto degli screening era a carico esclusivamente dei CCR in stadio I alla diagnosi. Dopo l’avvio
degli screening, l’incidenza è aumentata per tutte le sottosedi anatomiche del colon, in particolare per il colon distale.
L’avvio dei programmi di screening colorettale in Italia ha avuto un forte impatto portando a un aumento dell’incidenza
e delle forme precoci. E’ necessario un continuo monitoraggio delle aree italiane per capire gli effetti dello screening su
tutta la popolazione.
(Epidemiol Prev 2015; 39(3) Suppl 1: 115-125)
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MATERIALS AND METHODS
Data
The IMPATTO study collected data from CRC cases (Inter-
national Classification of Diseases, 10th revision: C18–C20)
in subjects aged 40-79 years that were diagnosed between
2000 and 2008 in the populations covered by 23 population-
based cancer registries (CR) in 13 Italian regions (Piemonte,
Liguria, Lombardia, Veneto, Trentino, Friuli-Venezia Giulia,
Emilia-Romagna, Toscana, Umbria, Lazio, Campania, Sicilia,
Sardegna). These areas included about 36%, 17%, and 24%
of the resident population in northern, central, and southern
Italy, respectively.
Cases based on death certificates only, autopsies without his-
tology, or autopsies with histology and incidence data equal to
date of death were excluded. All multiple metachronous cases
were included.
Collected data included incidence date, morphology and to-
pography, stage at diagnosis (according to Dukes’ classification
as modified by Astler and Coller39) and grading, surgical in-
tervention, lymph nodes examined and positive lymph nodes.
Multiple synchronous cases (incidence date within six months
from the index case) were recorded if located in different anatomic
sub-sites (fourth digit of the ICD-10 topography code) and only
the most advanced were staged. If more cancers were located in
the same sub-site, only the most advanced was recorded, main-
taining the recording rules of different morphologies.
Vital status was recorded for all cases up to either 31.12.2008
or 31.12.2010, according to the CR. Information about the
cause of death was collected for deceased subjects, according to
the International Classification of Diseases, 9th revision.
Tumour histological type was recorded according to the In-
ternational Classification of Diseases for Oncology, 3rd edition.
CRs carried out a record-linkage with the local SPs to retrieve
individual data on the screening history of patients before the
incidence date by collecting the date of the first invitation and
the dates of screening tests. Patients were then classified ac-
cording to the following screening patterns:
 screen-detected at the first screening episode;
 screen-detected at a repeat screening episode;
 screen-detected at follow-up;
 not compliant with diagnostic work-up after a positive screen-
ing test;
 subjects with at least one negative screening test before in-
cidence;
 never compliant (i.e., invited, but not tested within the SP);
 never invited to screening.
Two categories were then created according to the diagnostic
modality: screen-detected cases, including the first three classes,
and non-screen-detected cases, including the last four.
Finally, age- and sex-specific data on the resident population
in the study period for each CR were collected.
Analysis
Cases were classified by geographic macro-area according to the
Istat (Italian National Statistics Agency) classification: North-
west, Northeast, Centre, and South and Islands. They were
then grouped into two epidemiologically homogeneous areas,
North-Centre and South-Islands, apart from Latina, in the
southern part of the Lazio region (the centre of Italy), which
was included in the South-Islands according to its epidemio-
logical pattern.
During the study period, the CR included in the study only
SPs active in the North-Centre. The number of SPs increased
particularly in 2006, when the actual extension of invitations
rose to 51% of the target population (subjects aged 50-69
years) compared to 16% in 2005.11 In the IMPATTO study,
the proportion of screen-detected cases in subjects aged 50-69
years in the North-Centre rose from 9.1% in 2005 to 30.3%
in 2006 and reached 45.9% in 2008. Therefore, two periods
were identified, pre-2005 and from 2006 onward. Period-spe-
cific indicators were reported for areas where SPs were present.
Incidence rate trends (standardized on the 2001 European
population) were evaluated as a whole and by macro-area
(North-Centre and South-Islands), sex, ten-year age class,
anatomic site (proximal colon: C18.0-C18.4; distal colon:
C18.5-C18.8; colon NOS: C18.9; and rectum: C19-C20),
stage at diagnosis (according to Dukes’ classification), and
pattern of diagnosis (screen-detected, non-screen-detected).
The annual percent change (APC) of incidence rate trends,
with 95% confidence intervals (95%CI), were computed.
RESULTS
We collected data on 47,830 CRCs, of which 973 were ex-
cluded (775 anus and anal canal, 129 lymphomas, sarcoma, or
melanoma, and 69 for other reasons). The study archives used
in this paper are therefore the 46,857 CRCs diagnosed between
2000 and 2008 in subjects aged 40-79 years.
About one-sixth of the cases (15.7%) were from the South and
the Islands (table 1, p. 118). Most cases were male (58%) and
in the upper age class (70-79 years, 44.8%).
There were 3,164 screen-detected cases (6.8% of the total; the
proportion increased to 16.6% when considering only cases of
50- to 69-year-olds from areas with an SP).
One third of the cases were in the rectum. The stage was
available for 87.6% of the cases.
Overall, the incidence rate was 133.7 and 83 per 100,000 in
males and females, respectively.
The incidence in the North-Centre was higher than in the
South-Islands: 141 vs 103.9 x 100,000 in men and 86.4 vs 69.4
x 100,000 in women.
As shown in table 2 (p. 118), the CRs took part in the study
with cases from different periods. Moreover, the SPs were in-
troduced in different years.
Standardized incidence rates of single CRs over the entire study
period were between 153.4 inGenova and 99.1 in Sassari inmen
and between 94.8 in Genova and 65.6 in Sassari in women.
In the North-Centre, incidence rose more steeply from 2006
in both genders, the year that many SPs were implemented in
this macro-area (figure 1, p. 119). In the South and on the Is-
lands, the figure was stable for both genders.
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Geographic Cancer registry Cases Incidence rate (x 100,000)
area (N) 2000 2001 2002 2003 2004 2005 2006 2007 2008
Northwest Genova 2,014 112.1 105.7 102.1
Milano 6,019 104.8 108.1 102.0 101.9 102.5 90.0 107.4
Sondrio 875 91.7 88.8 101.1 95.1 89.7 90.6 130.4 120.7 110.2
Biella 893 104.3 88.4 111.6 99.9 115.3 100.5 107.3
Northeast Trentino 1,215 91.5 92.2 88.1 90.0 95.8
Veneto 1,894 97.9 109.5 107.7 119.5 118.8 110.8
Friuli-Venezia Giulia 2,336 105.6 104.8 98.9
Emilia-Romagna 17,017 120.2 104.1 112.4 108.0 109.5 117.4 139.5 117.3 113.4
Centre Firenze-Prato 3,935 111.9 113.0 112.5 106.4 106.3 107.2
Umbria 3,289 111.7 115.6 111.6 142.3 128.2
South/Islands Latina 932 89.7 86.4 85.3 87.3
Napoli 945 83.3 77.2 98.2 84.8 90.5
Siracusa 821 81.1 79.7 83.9 83.6 79.1
Palermo 1,628 86.3 87.6 86.9
Catania-Messina 2,236 78.6 87.3 84.4
Sassari 808 87.9 86.8 82.6 79.1
Numbers in color represent the years when a screening programme was active
Table 2. Number of colorectal cancer cases and incidence rates (standardized Eu 2001) by cancer registry and year. Males and females aged 40-79 years.
Tabella 2. Casi di tumore del colon retto e tassi standardizzati di incidenza (popolazione europea 2001) per Registro tumori e anno. Uomini e donne, età 40-79 anni.
N %
Total 46,857 100
Macro-area
North-Centre 39,487 84.3
South-Islands 7,370 15.7
Gender
male 27,195 58.0
female 19,662 42.0
Age (years)
40-49 2,180 4.7
50-59 7,741 16.5
60-69 15,927 34.0
70-79 21,009 44.8
Pattern of diagnosis (all areas, age 40-79 years)
screen-detected at the first screening episode 2,897 6.2
screen-detected at a repeat screening episode 220 0.5
screen-detected at follow-up 47 0.1
not compliant with work-up after a positive screening test 116 0.2
subjects with a negative screening test before incidence 862 1.8
never compliant (i.e., invited but without a screening test) 2,102 4.5
never invited to screening 40,613 86.7
Pattern of diagnosis (areas with a screening programme, age 50-69 years)
screen-detected 2,805 16.6
non-screen-detected 14,061 83.4
Anatomic site
proximal colon 13,772 29.4
distal colon 16,278 34.7
rectum 14,278 30.5
colon NOS 2,529 5.4
Stage at diagnosis (Dukes)
I 8,218 17.5
II 12,051 25.7
III 12,206 26.0
IV 8,577 18.3
unknown 5,805 12.4
Table 1. Main characteristics
of the study subjects.
Tabella 1. Principali caratte-
ristiche dei soggetti studiati.
The increase observed in the North-Centre regarded only
those areas where SPs were implemented, with the APC in ar-
eas without SP being -0.7 (95%CI -4.3 to 3.1) for males and
-2.5 (95%CI -5.6 to 0.7) for females (table 3).
The trends in the South and on the Islands showed a non-sig-
nificant increase in males (APC 2.5; 95%CI -0.6 to 5.7) and
a decrease in females (APC -0.4; 95%CI -3.0 to 2.2).
In the North-Centre with an SP present, we recorded a non-
significant increase in males 50-69 years old (APC 3.6; 95%CI
-0.1 to 7.4) and in females 50-69 years old (APC 2.3; 95%CI
-0.8 to 5.4), while the 40-49 and 70-79 year age classes showed
small, non-significant decreases.
In the North-Centre without SPs no significant trends were ob-
served in the age class of 50-69 years, while in the South and
on the Islands incidence increased in males (APC 4.4; 95%CI
0.4 to 8.5) and overall (APC 3.3; 95%CI 1.3 to 5.3).
Figure 2 (p. 120) shows incidence rates by age in areas with an
SP, on a time scale centred on the year of implementation of
screening. The pre-screening incidence rates of the four 10-year
age classes were stable. During the first two years after screen-
ing started, incidence rates increased in all age groups, apart
from the youngest, and then decreased. The increase was
higher in subjects aged 60-69 years, whose incidence rates
shifted from 169 to 249 cases per 100,000 (+47.3%) as op-
posed to subjects 50-59 years old (+21.7%). The decrease in
incidence after year 2 was evident both in subjects aged 60-69
years (APC -5.7; 95%CI -28.3 to 24.2) and in those older than
70 years (APC -7.4; 95%CI -22.7 to 11.0).
In subjects aged 50-69 years, the pre-screening incidence rates
were similar to those of areas without SPs in the North-Centre,
and became significantly higher after the implementation of SPs
(table 4, p. 120). Incidence rates in the South and on the Islands
were lower. In particular, pre-screening incidence rates in the
North-Centre were generally comparable to North-Centre
Colorectal cancers incidence trends: IMPATTO study
119 NATIONAL CENTRE SCREENING MONITORING 11TH REPORTEpidemiol Prev 2015; 39(3) Suppl 1: 1-125
anno 39 (3) maggio-giugno 2015e&p
Males Females Total
APC 95%CI APC 95%CI APC 95%CI
North-Centre with SP
40-79 years 2.5 -0.3 ; 5.4 1.3 -0.8 ; 3.5 2.2 -0.1 ; 4.5
50-69 years 3.6 -0.1 ; 7.4 2.3 -0.8 ; 5.4 3.1 -0.1 ; 6.5
North-Centre with SP
pre-screening
40-79 years 0.2 -1.7 ; 2.2 1.7 -1.9 ; 5.4 1.1 -0.1 ; 2.4
50-69 years 0.4 -2.3 ; 3.1 1.8 -1.9 ; 5.7 1.2 -0.7 ; 3.1
North-Centre with SP
post-screening
40-79 years 2.5 -0.3 ; 5.4 1.3 -0.8 ; 3.5 1.8 -0.8 ; 4.4
50-69 years 3.6 -0.1 ; 7.4 2.3 -0.8 ; 5.4 2.5 -1.1 ; 6.2
North-Centre without SP
40-79 years -0.7 -4.3 ; 3.1 -2.5 -5.6 ; 0.7 -1.3 -3.6 ; 1.1
50-69 years -2.0 -6.4 ; 2.6 -2.7 -9.1 ; 4.2 -2.0 -5.1 ; 1.2
South and the Islands
40-79 years 2.5 -0.6 ; 5.7 -0.4 -3.0 ; 2.2 1.3 -0.4 ; 3.0
50-69 years 4.4 0.4 ; 8.5 1.5 -2.2 ; 5.3 3.3 1.3 ; 5.3
Table 3. Annual percent
change (APC), with 95% con-
fidence intervals, of incidence
rates by macro-area, imple-
mentation of screening pro-
gramme (SP), age class, and
gender. Years 2000-2008.
Tabella 3. Annual percent
change (APC) dei tassi di inci-
denza (con intervalli di confi-
denza al 95%) per macroarea,
presenza di programmi di
screening (SP), classe d’età e
genere. Anni 2000-2008.
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Figure 1. Trends of incidence rates
(standardized Eu 2001) by macro-
area and gender.Ages 40-79 years.
Figura 1. Andamento temporale
dei tassi standardizzati di incidenza
(popolazione europea 2001) per
macroarea e genere. Età 40-79
anni.
APC (95%CI)
NORTH-CENTRE
males (2000-2008) 2.1 (0.1 ; 4.1)
females (2000-2008) 1.3 (-0.2 ; 2.7)
SOUTH-ISLANDS
males (2001-2007) 2.5 (-0.6 ; 5.7)
females (2001-2007) -0.4 (-3.0 ; 2.2)
males North-Centre
females North-Centre
males South-Islands
females South-Islands
without screening for all categories of the variables studied, apart
from females (+7.5%) and those younger in age (+5.2%). In-
stead, the respective incidence rates were higher in the North-
Centre post-screening and lower in the South and on the Islands
for all variables, except for stage IV at diagnosis.
We could not compare the incidence rates by anatomic site of
the different areas, because the proportion of colon NOS in the
North-Centre without active SPs was too high and unevenly dis-
tributed during the years of the study.
Analysis by stage at diagnosis
In the North-Centre without active SPs, and in the South and
on the Islands, incidence rates by stage were stable (apart from
some fluctuations in the North-Centre during the early years
(figures 3 and 4). The APCs for both macro-areas were not
significant.
Instead, stage-specific incidence rates in the North-Centre
with active SPs showed two different phases (figure 5). Before
screening, the incidence rates of stage II, III, and IV cases were
stable while those of stage I increased. In fact, during the years
before screening the proportion of cases for which the stage was
not available decreased. We therefore carried out a sensitivity
analysis attributing to such cases the distribution by stage ob-
served among the cases whose stage was known. The pre-
screening incidence rates obtained in this way showed a smaller
but still significant increase for stage I cases (+5.7 x 100,000
over the entire period).
During the screening period, the incidence rates of stage I cases in-
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Figure 2. Trends in incidence rates
by age class. Cancer registries of ar-
eas with screening programme
only. The time scale is centred on
the year the programme was im-
plemented.
Figura 2. Andamento temporale
dei tassi di incidenza per classe
d’età. Solo registri tumori di aree
dove è attivo un programma di
screening. La scala temporale è
centrata sull’anno in cui il pro-
gramma è stato attivato.
70-79 years
60-69 years
50-59 years
40-49 years
screening start
North-Centre North-Centre South-Islands
without with screening programme
screening pre-screening post-screening
programme
incidence incidence p-value* incidence p-value* incidence p-value*
rates rates rates rates rates
Overall 112.1 116.3 0.10 137.1 <0.001 93.7 <0.001
Gender
male 142.2 144.0 0.66 170.5 <0.001 112.3 <0.001
female 84.2 91.7 0.02 106.8 <0.001 76.9 <0.001
Age (years)
50-59 72.9 78.1 0.07 89.7 <0.001 62.2 <0.001
60-69 168.9 171.4 0.59 205.5 <0.001 139.1 <0.001
Pattern of diagnosis
screen-detected - - - 37.4 - - -
non-screen-detected 112.1 116.3 0.10 99.7 <0.001 93.7 <0.001
Stage at diagnosis
(Dukes)
I 18.0 18.6 0.57 32.8 <0.001 11.7 <0.001
II 26.9 29.2 0.08 31.7 <0.001 22.5 <0.001
III 31.4 32.4 0.45 36.6 <0.001 21.4 <0.001
IV 23.2 23.1 0.89 22.0 0.28 21.1 0.18
unknown 12.6 13.1 0.64 13.9 0.14 16.9 <0.001
* compared to reference = North-Centre without screening programme
Table 4. Incidence rates
(standardized Eu 2001) by
macro-area, implementation
of screening programme and
period with respect to diffe-
rent characteristics, x 100,000.
Ages 50-69 years.
Tabella 4. Tassi standardiz-
zati di incidenza (popolazione
europea 2001) per macroa-
rea, con e senza screening,
per periodo, x 100.000. Età
50-69 anni.
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Figure 5. Trends in incidence rates
(standardized Eu 2001) by stage
at diagnosis. Only areas with a
screening programme. Ages 50-69
years. The time scale is centred on
the year of implementation of the
screening programme.
Figura 5. Andamento temporale
dei tassi standardizzati di incidenza
(popolazione europea 2001) per
stadio alla diagnosi. Solo aree con
programmi di screening attivi. Età
50-69 anni. La scala temporale è
centrata sull’anno in cui il pro-
gramma è stato attivato.
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Figure 3. Trends in incidence rates
(standardized Eu 2001) by stage
at diagnosis. North-Centre with no
screening programme. Ages 40-79
years.
Figura 3. Andamento temporale
dei tassi standardizzati di incidenza
(popolazione europea 2001) per
stadio alla diagnosi. Centro-Nord
senza programmi di screening. Età
40-79 anni.
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Figure 4. Trends in incidence rates
(standardized Eu 2001) by stage
at diagnosis. South-Islands. Ages
40-79 years.
Figura 4. Andamento temporale
dei tassi standardizzati di incidenza
(popolazione europea 2001) per
stadio alla diagnosi. Sud-Isole. Età
40-79 anni.
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screening start
creased from19.5 to 44.7 x 100,000 in the 2nd year, those of stage
II from 30.3 to 35.8 x 100,000, while stage III and IV cases were
quite stable, their sum ranging between 68 and 73 cases x 100,000.
In the North-Centre with no active SP during the final years
of the study, stage I cases increased by 7.5 percent points and
stage IV cases by 4.6 points, while stage III cases decreased by
7.4 points and the proportion of cases with unavailable stage
also declined (table 5).
In the South and on the Islands, no variation occurred during
the study period. A relevant proportion of cases were stage IV
(21.3%), while stage I cases were 12.8%, lower than in the
North-Centre. The proportion of cases with an unknown
stage was around 20%.
In areas with an SP, the proportion of stage I cases in subjects
aged 50-69 years increased from 16% before SP implementa-
tion to 26.7% after, while stage III and stage IV cases decreased
respectively by 2.0 and 4.2 percent points.
Analysis by anatomic site
The proportion of colon NOS in the North-Centre with no
active SP was too high to produce the incidence rates without
SP by site for the North-Centre.
In the South-Islands macro-area, incidence rates in the proximal
colon decreased, while those in the distal colon were stable and
those in the rectum increased (figure 6). Only the latter trend
was statistically significant (APC 3.0; 95%CI 0.3 to 5.7).
In areas where SPs were implemented, the pre-screening trend
for all sites was stable (figure 7). When the SPs started, we
recorded a steep increase of incidence rates in the distal colon
(from 43.9 to 69.3 x 100,000 in the 2nd year) and, to a lesser
extent, in the proximal colon (from 32.3 to 40.9 x 100,000)
and the rectum (from 36.7 to 45.5 x 100,000). This increase
ended two years after the implementation of screening and was
followed by a reduction in the rates for all three sites.
DISCUSSION
We evaluated CRC incidence rates in Italy from the early
2000s, with particular regard to the effects of the implemen-
tation of the SPs introduced during that period in several ar-
eas of the country.
Overall, we observed a remarkable difference between the
North-Centre and the South and Islands, with the incidence
rates in the former macro-area being much higher than in the
latter. A different risk of CRC throughout the country, mainly
attributed to different exposure to risk factors (e.g., diet), had
already been reported.28
Of the areas included in the study, SPs had been implemented
only in the North-Centre and showed a significant effect on in-
cidence rates. As expected, a sharp increase in incidence was ob-
served in the first years of screening, the prevalence round,29
followed by a decrease that started quite soon, i.e., within 3-4
years of screening start. For subjects aged 70-79 years, the in-
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Figure 6. Trends in incidence
rates (standardized Eu 2001) by
anatomic site. South-Islands. Ages
40-79 years.
Figura 6. Andamento temporale
dei tassi standardizzati di incidenza
(popolazione europea 2001) per
sede anatomica. Sud-Isole. Età 40-
79 anni.
colon NOS
proximal colon
distal colon
rectum
North-Centre without screening South/Islands North-Centre with screening
programme 40-79 years 40-79 years programme 40-69 years
Stage 2000-2006 2006-2008 2001-2007 pre-screening post-screening
(N=4,488) (N=1,805) (N=7,370) (N=6,713) (N=8,186)
I 13.7 21.2 12.8 16.0 26.7
II 25.6 25.5 23.9 25.3 23.2
III 29.1 21.7 23.1 27.8 25.8
IV 18.1 22.7 21.3 19.6 15.4
unknown 13.4 8.9 18.8 11.3 8.8
Table 5. Distribution by stage
at diagnosis, by macro-area
with and without a screening
programme, and by period (%).
Tabella 5. Distribuzione per
stadio alla diagnosi, per ma-
croarea, con e senza un pro-
gramma di screnning, per pe-
riodo (%).
cidence trend after the prevalence round is suggestive of a de-
crease to values lower than the pre-screening level.
The overall increase is evident even when considering the
whole age range included in the study (40-79 years), which
exceeds the specific target population of screening, as well as
in the national statistics regarding all ages (0-85+ years).2 It
is of utmost importance that such trends be correctly inter-
preted in terms of any transient effect related to the imple-
mentation of screening and not as an increased risk of CRC
in the population.
SPs increased the incidence gap between macro-areas: in the
South and on the Islands, no significant trend was observed,
in either gender, nor in the pre-screening in those areas where
screening was implemented. After the introduction of SPs, the
increase in incidence was more evident in the 60-69 year age
class than in the 50-59 year one. A differential effect of FIT
with age has been described.30We also observed a small, non-
significant but consistent increase in both genders and across
centres, in the age classes above 70 years (probably related to
a significant proportion of screen-detected cases in that age
group: 15.1% in the 70-74 year class – the SP of Umbria is
aimed at residents aged from 50 to 74 years). We do not have
enough power to observe even considerably strong trends in the
youngest age class because incidence is quite low. Nonetheless,
our data suggest a decreasing trend.
These figures are highly suggestive of the expected increase in
incidence rates that the introduction of SPs produces through
the anticipated diagnosis of cases that otherwise would emerge
later and, in part, through a (hard to quantify) number of
over-diagnoses.
One relevant aspect analyzed regards the impact of screening
on incidence trends by stage at diagnosis. In the areas where an
SP was implemented, we recorded a pre-screening trend only
for stage I cases. This could be related to a spontaneous (i.e.,
in the absence of a population-based SP) increased spread of
colonoscopies in the population. The implementation of SPs
modified exclusively the rates of stage I cases, with the “clas-
sic” pattern of initial increase and subsequent reduction in in-
cidence. None of the other stages were affected by screening.
This suggests that diagnostic anticipation takes place mainly for
cases at an initial stage.
Our data do not allow us to assess the issue of over-diagnosis,
mainly because the follow-up period for SPs is too short to de-
termine whether the decrease in incidence observed beginning
in the 3rd year will reach the level of pre-screening incidence
or drop even lower. However, it has been argued that over-di-
agnosis of invasive CRC is not a worrisome phenomenon in
CRC screening, because the removal of precancerous lesions
(i.e., advanced adenomas) determines a relevant incidence
reduction.31-34
Screening is expected to reduce the incidence rates of advanced
stages. We did not notice such an effect, probably because the
slow implementation of SPs is still delaying the end of the preva-
lence round. In fact, only a few programmes have invited the
entire target population within the first two years, and all Ital-
ian programmes have seen quite low participation rates. Con-
sequently, the proportion of first screening tests is very high even
3 or 4 years after programme start, due to people being invited
for the first time or those who did not respond to the first in-
vitation and decided to respond to a second one. Only a longer
follow-up period and a more detailed analysis of the cohorts ac-
tually invited or participating will make it possible to confirm
any effect of screening on the incidence of advanced cancers and
incidence as a whole. It is worth underlining that none of the
studies evaluating the impact of colorectal screening on inci-
dence rates have found a cumulative reduction of incidence
within 5 years of starting to screen,16,20 including those based
on flexible sigmoidoscopy.35-36
Differently from areas with SPs, both the North-Centre with-
out SPs and the South and Islands did not record any signifi-
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Figure 7. Trends in incidence rates
(standardized Eu 2001) by anatomic
site. Cancer registries only of areas
with a screening programme. Ages
50-69 years. The time scale is cen-
tred on the year of implementation
of the screening programme.
Figura 7. Andamento temporale
dei tassi standardizzati di incidenza
(popolazione europea 2001) per
sede anatomica. Solo registri tu-
mori di aree dove è attivo un pro-
gramma di screening. Età 50-69
anni. La scala temporale è centrata
sull’anno in cui il programma è
stato attivato.
rectum
distal colon
proximal colon
colon NOS
screening start
cant trend at any stage of diagnosis. However, notwithstand-
ing the lower overall incidence rates, the specific rates of stage
IV in the South and on the Islands were comparable to the
other areas of the country. This figure may be attributed to a
delay of diagnosis in this macro-area. The lack of any decrease
during the study period suggests that no improvements took
place to enhance the anticipation of CRC diagnosis. Thus, the
widespread implementation of SPs in this macro-area seems
particularly relevant.
Unfortunately, we could not evaluate incidence trends by
anatomic site in the northern-central areas without SPs, due to
a high percentage of missing data. In the South and on the Is-
lands, incidence trends by site showed a significant increase for
the rectum.
In areas with SPs, the pre-screening rates in the proximal
colon, distal colon, and rectum were stable. After SP started,
incidence increased in all anatomic sites, particularly in the dis-
tal colon. This figure is in line with the results of many stud-
ies that have shown a higher sensitivity for advanced neopla-
sia in the left versus right colon with faecal occult blood
testing37 and colonoscopy.38
The major strength of this study is the large number of cases
included in the analysis and the quality of the data collected.
The study is based on almost 47,000 CRCs collected by a large
number of cancer registries throughout the entire country,
and thus offers the best available representation of CRC epi-
demiology in Italy in relation to SP implementation. On the
other hand, the areas included in this study represent a relevant
proportion (27% overall) of the national population, but the
various macro-areas are unevenly represented. Therefore, pro-
jecting our results to the whole country should be done with
caution.
This study also has several limits. First, the results of this
study do not exclusively reflect the performance of the screen-
ing protocols utilised by SPs (first level test and further assess-
ment), but were very much influenced by the spread of screen-
ing in the target population, a result associated with the
effective extension of invitations and compliance with the in-
vitation to a first-level test, as well as diagnostic workup for sub-
jects with a positive test, etc. These figures are quite different
among programmes and make generalizations difficult. This
implies that our results should be regarded as purely indicative
of what can be expected when implementing an SP, but the fig-
ures obtained in a different setting may be very different.
Second, the study only included the few years since screening
started. Therefore it could not show how long the decrease in
incidence rates, following the initial peak, might last and the
size of the reduction that could be achieved.
CONCLUSION
We described the trends of CRC incidence rates in Italy from
2000 to 2008, when several SPs were implemented in differ-
ent areas. The differential figures introduced by the imple-
mentation of SPs warrant a continuous surveillance of CRC in-
cidence and mortality trends to monitor the impact of
screening at a national level.
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